- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Sarcoma
Volume 2011 (2011), Article ID 863210, 5 pages
doi:10.1155/2011/863210
Current Therapeutic Approaches in Metastatic and Recurrent Ewing Sarcoma
Division of Pediatric Hematology/Oncology, Department of Pediatrics, H085, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State Hershey Children's Hospital, 500 University Drive, P.O. Box 850, Hershey, PA 17033-0850, USA
Received 30 August 2010; Accepted 2 November 2010
Academic Editor: Ole Nielsen
Copyright © 2011 Michael Huang and Kenneth Lucas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Ewing sarcoma (ES) is the second most common type of primary bone malignancy in children and young adults. Survival rates for localized ES have improved to upwards of 70% with aggressive chemotherapy and local control. On the other hand, there has been little improvement in survival rates for patients with metastatic or recurrent ES. Herein we review the different current therapeutic approaches available, including the different upfront and salvage chemotherapy regimens, the role for stem cell transplantation, and potential use of immunotherapy.